Back to Search
Start Over
First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel
- Source :
- Frontiers in Pharmacology
- Publication Year :
- 2017
- Publisher :
- Frontiers Media SA, 2017.
-
Abstract
- Introduction: We performed a chart review study in our castration-resistant prostate cancer (CRPC) patients who received Abiraterone acetate (AA) treatment after docetaxel and identified clinical markers which can predict treatment outcome. Materials and Methods: From 2012 to 2016, 64 patients who received docetaxel after CRPC followed by AA treatment were included. Clinical parameters were recorded and analysis was performed to identify associations between pre-treatment variables and treatment outcome. Results: Thirty three patients (51.6%) achieved a decrease in PSA of 50%. The median PSA progression-free survival and overall survival in the total cohort of 64 patients were 6.6 and 24 months, respectively. Adverse events (AEs) in all grades developed in 35.9% (23/64) patients and mostly were grade 1 or 2. The most common AEs were gastric upset, hypokalemia and elevated liver function tests. Of the eight variables analyzed, first line androgen deprivation therapy (ADT) duration showed positive association to progression free survival (HR 0.98, 95% CI [0.96–0.99], p = 0.012) and overall survival (HR 0.97, 95% CI [0.94–0.99], p = 0.019). Pre-AA PSA and PSA progression ratio showed negative association only to progression free survival (HR 1.0, 95% CI [1.000–1.002], p = 0.025, HR 1.01, 95% CI [1.00–1.01], p < 0.001, respectively). Conclusion: First line ADT duration was positively associated with AA treatment efficacy in progression free survival and overall survival. It can be used as a pre-treatment predictor.
- Subjects :
- Oncology
medicine.medical_specialty
030232 urology & nephrology
androgen deprivation therapy
Androgen deprivation therapy
PSA
03 medical and health sciences
chemistry.chemical_compound
Prostate cancer
0302 clinical medicine
Internal medicine
medicine
castration-resistant prostate cancer
docetaxel
Pharmacology (medical)
Progression-free survival
Adverse effect
Original Research
Pharmacology
business.industry
Abiraterone acetate
medicine.disease
Hypokalemia
abiraterone acetate
chemistry
Docetaxel
030220 oncology & carcinogenesis
Cohort
medicine.symptom
business
medicine.drug
Subjects
Details
- ISSN :
- 16639812
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Frontiers in Pharmacology
- Accession number :
- edsair.doi.dedup.....3b07e8b62cd758250bb0cc920bb863af